A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body

A Phase 1-2 Ascending Dose Study to Assess the Pharmacodynamics, Pharmacokinetics, and Safety of HSP-130 in Subjects With Non-Metastatic Breast Cancer Following Single-Dose and Multiple-Dose Administration by Subcutaneous Injection

Category & Conditions:
Cancer
Medicine:
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C1221002
Open Plain Language Summary Result:Click here